Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.

Hasumi, Y., Baba, M., Ajima, R., Hasumi, H., Valera, V.A., Klein, M.E., Haines, D.C., Merino, M.J., Hong, S.B., Yamaguchi, T.P., Schmidt, L.S., Linehan, W.M.
Journal   Proc Natl Acad Sci USA.
Species  
Analytes Measured   Akt , p70S6K , S6RP
Matrix Tested   Kidney tumor cell lysates
Year   2009
Volume   106
Page Numbers   18722-7
Application   Phosphoproteins
Abstract
Germline mutations in the BHD/FLCN tumor suppressor gene predispose patients to develop renal tumors in the hamartoma syndrome, Birt-Hogg-Dubé (BHD). BHD encodes folliculin, a protein with unknown function that may interact with the energy- and nutrient-sensing AMPK-mTOR signaling pathways. To clarify BHD function in the mouse, we generated a BHD knockout mouse model. BHD homozygous null (BHD(d/d)) mice displayed early embryonic lethality at E5.5-E6.5, showing defects in the visceral endoderm. BHD heterozygous knockout (BHDd(/+)) mice appeared normal at birth but developed kidney cysts and solid tumors as they aged (median kidney-lesion-free survival = 23 months, median tumor-free survival = 25 months). As observed in human BHD kidney tumors, three different histologic types of kidney tumors developed in BHD(d/+) mice including oncocytic hybrid, oncocytoma, and clear cell with concomitant loss of heterozygosity (LOH), supporting a tumor suppressor function for BHD in the mouse. The PI3K-AKT pathway was activated in both human BHD renal tumors and kidney tumors in BHD(d/+) mice. Interestingly, total AKT protein was elevated in kidney tumors compared to normal kidney tissue, but without increased levels of AKT mRNA, suggesting that AKT may be regulated by folliculin through post translational or post-transcriptional modification. Finally, BHD inactivation led to both mTORC1 and mTORC2 activation in kidney tumors from BHD(d/+) mice and human BHD patients. These data support a role for PI3K-AKT pathway activation in kidney tumor formation caused by loss of BHD and suggest that inhibitors of both mTORC1 and mTORC2 may be effective as potential therapeutic agents for BHD-associated kidney cancer.

View Publications

Related Products

Phospho-Akt (Ser473) Antibody
Akt
Total Akt Antibody Bulk Product
Akt
Phospho-Akt (Ser473) Kit
Akt | Human, Mouse, Rat, Non-human primate
Singleplex
Total Akt Kit
Akt | Human, Mouse, Rat, Non-human primate
Singleplex
Akt Control Pack 1
Akt
Akt Signaling Whole Cell Lysate Kit
Akt, GSK-3β, p70S6K | Human, Mouse, Rat
Multiplex
Akt Signaling Panel II Whole Cell Lysate Kit
Akt, GSK-3β, p70S6K, S6RP | Human, Mouse, Rat
Multiplex
Phospho(Ser240/244)/Total S6RP Whole Cell Lysate Kit
S6RP | Human, Mouse, Rat
Multiplex
Total S6RP Whole Cell Lysate Kit
S6RP | Human, Non-human primate, Mouse, Rat
Singleplex
Phospho(Ser473)/Total Akt Whole Cell Lysate Kit
Akt | Human, Mouse, Rat
Multiplex
Phospho-p70S6K (Thr389) Whole Cell Lysate Kit
p70S6K | Human, Mouse, Rat
Singleplex
Phospho-p70S6K (Thr421/Ser424) Whole Cell Lysate Kit
p70S6K | Human, Mouse
Singleplex
Total p70S6K Whole Cell Lysate Kit
p70S6K | Human, Mouse, Rat
Singleplex
Akt Signaling (Total Protein) Whole Cell Lysate Kit
Akt, GSK-3β, p70S6K | Human, Mouse, Rat
Multiplex
Phospho (Thr421/Ser424)/Total p70S6K Whole Cell Lysate Kit 5
p70S6K | Human, Mouse, Rat
Multiplex
Phospho-Akt (Thr308) Whole Cell Lysate Kit
Akt | Human, Mouse
Singleplex
Phospho-S6RP (Ser240/244) Whole Cell Lysate Kit
S6RP | Human, Mouse, Rat
Singleplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters